KNSA · Insider Trading
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Every open-market purchase and sale reported by KNSA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Sanj K Patel | CHAIRMAN & CEO | MIXED | +16,174 | −$1.20M |
| 2026-09-03 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | +4,700 | −$349.15K |
| 2026-09-03 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | +4,299 | −$319.42K |
| 2026-09-03 | Ross Moat | CHIEF OPERATING OFFICER | MIXED | +4,278 | −$317.67K |
| 2026-09-03 | Michael R Megna | CHIEF ACCOUNTING OFFICER | MIXED | +1,644 | −$798.53K |
| 2026-09-03 | Sanj K Patel | CHAIRMAN & CEO | MIXED | +16,174 | −$1.20M |
| 2026-08-21 | Barry D Quart | Director | G | −2,600 | — |
| 2026-08-04 | Richard S Levy | Director | M | +403 | — |
| 2026-07-31 | G Bradley Cole | Director | MIXED | −8,173 | −$299.09K |
| 2026-07-06 | Dhiraj H Malkani | CHIEF STRATEGY OFFICER | A | +103,459 deriv. | — |
| 2026-06-02 | G Bradley Cole | Director | M | +2,799 | — |
| 2026-06-02 | Tracey L McCain | Director | M | +2,799 | — |
| 2026-06-02 | Barry D Quart | Director | M | +2,799 | — |
| 2026-06-02 | Kimberly J Popovits | Director | M | +2,799 | — |
| 2026-06-02 | Richard S Levy | Director | M | +2,799 | — |
| 2026-06-02 | Sanj K Patel | CHAIRMAN & CEO | C | +900,000 | — |
| 2026-06-02 | Thomas Malley | Director | M | +2,799 | — |
| 2026-06-02 | Felix Baker | Director | A | +72,936 | — |
| 2026-05-05 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | — | −$2.53M |
| 2026-05-01 | Sanj K Patel | CHAIRMAN & CEO | MIXED | — | −$1.12M |
| 2026-04-29 | Barry D Quart | Director | MIXED | — | −$468.55K |
| 2026-04-13 | Ross Moat | CHIEF OPERATING OFFICER | Sell | −1,703 | −$79.51K |
| 2026-04-13 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sell | −6,625 | −$309.32K |
| 2026-04-08 | Eben Tessari | CHIEF STRATEGY OFFICER | MIXED | +1,880 | −$41.40K |
| 2026-04-08 | Ross Moat | CHIEF OPERATING OFFICER | MIXED | −664 | −$152.87K |
| 2026-04-08 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | +1,289 | −$59.12K |
| 2026-04-08 | Sanj K Patel | CHAIRMAN & CEO | MIXED | +5,160 | −$525.00K |
| 2026-04-08 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | +1,391 | −$63.77K |
| 2026-04-08 | Michael R Megna | CHIEF ACCOUNTING OFFICER | MIXED | +2,266 | −$77.60K |
| 2026-04-08 | Barry D Quart | Director | MIXED | — | −$246.16K |
| 2026-04-03 | Michael R Megna | CHIEF ACCOUNTING OFFICER | MIXED | +4,731 | −$145.27K |
| 2026-04-03 | Eben Tessari | CHIEF STRATEGY OFFICER | MIXED | +4,584 | −$75.70K |
| 2026-04-03 | Ross Moat | CHIEF OPERATING OFFICER | MIXED | +4,981 | −$60.87K |
| 2026-04-03 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | +2,677 | −$120.81K |
| 2026-04-03 | Sanj K Patel | CHAIRMAN & CEO | MIXED | +11,014 | −$496.36K |
| 2026-04-03 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | +3,010 | −$135.77K |
| 2026-03-11 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | −$926.35K |
| 2026-03-04 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | — | −$1.38M |
| 2026-02-12 | Barry D Quart | Director | MIXED | — | −$82.68K |
| 2026-02-11 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | −7,000 | −$621.88K |
| 2026-02-04 | Richard S Levy | Director | M | +683 | — |
| 2026-02-04 | Barry D Quart | Director | MIXED | — | −$474.73K |
| 2026-01-09 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sell | −12,000 | −$502.68K |
| 2025-12-17 | Eben Tessari | CHIEF OPERATING OFFICER | MIXED | −6,048 | −$447.73K |
| 2025-12-17 | Barry D Quart | Director | MIXED | — | −$627.02K |
| 2025-12-10 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | −$1.29M |
| 2025-12-01 | Eben Tessari | CHIEF OPERATING OFFICER | MIXED | — | −$4.00K |
| 2025-11-19 | Eben Tessari | CHIEF OPERATING OFFICER | MIXED | −5,970 | −$456.83K |
| 2025-11-14 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | −$199.20K |
| 2025-11-14 | Sanj K Patel | CHAIRMAN & CEO | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Felix Baker | Director | 2,759,734 | $201.41M |
| Julian Baker | Director | 2,753,656 | $200.96M |
| Sanj K Patel | CHAIRMAN & CEO | 92,348 | $6.74M |
| Thomas Malley | Director | 87,312 | $6.37M |
| John F. Paolini | CHIEF MEDICAL OFFICER | 69,922 | $5.10M |
| Michael R Megna | CHIEF ACCOUNTING OFFICER | 33,662 | $2.46M |
| Eben Tessari | CHIEF STRATEGY OFFICER | 23,976 | $1.75M |
| Richard S Levy | Director | 22,359 | $1.63M |
| Mark Ragosa | CHIEF FINANCIAL OFFICER | 22,189 | $1.62M |
| Kimberly J Popovits | Director | 15,345 | $1.12M |
| Tracey L McCain | Director | 15,345 | $1.12M |
| Ross Moat | CHIEF OPERATING OFFICER | 14,506 | $1.06M |
| Barry D Quart | Director | 12,745 | $930.13K |
| G Bradley Cole | Director | 11,672 | $851.82K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KNSA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.